The research company Dextech Medical announces that recruitment to the company's myeloma study has been completed and that the preliminary results are very positive. All patients responded to treatment with OsteoDex by the disease going from progressive to stable during the treatment period, the company says.The primary objective of safety and tolerability was met without any significant treatment-related adverse events. Just over 70 percent of the patients also maintained stable disease after the end of treatment. The company continues to follow the patients in the highest-dose group, which means that the final study report will only be completed when the results from the extended follow-up are available."We are now compiling strong data to present to our stakeholders as soon as the remaining long-term follow-up data are available. We feel very optimistic in light of the study data and a unique MOA," says CEO Anders R Holmberg in a comment. Study results are very important for companies such as Dextech.